For most biotech founders, the Series A raise is the first time the spotlight really turns on. Investors aren’t just evaluating your science anymore—they’re evaluating the business wrapped around it. They want to know: Does this company have what it takes to scale without falling apart?

Change how you do change management.

You think your org can benefit from a VPN; so now what? What considerations should you weigh to make the best, most economical decision?